Global Perspective on Telemedicine for Parkinson's Disease

J Parkinsons Dis. 2021;11(s1):S11-S18. doi: 10.3233/JPD-202411.

Abstract

Telemedicine programs are particularly suited to evaluating patients with Parkinson's disease (PD) and other movement disorders, primarily because much of the physical exam findings are visual. Telemedicine uses information and communication technologies to overcome geographical barriers and increase access to healthcare service. It is particularly beneficial for rural and underserved communities, groups that traditionally suffer from lack of access to healthcare. There is a growing evidence of the feasibility of telemedicine, cost and time savings, patients' and physicians' satisfaction, and its outcome and impact on patients' morbidity and quality of life. In addition, given the unusual current situation with the COVID-19 pandemic, telemedicine has offered the opportunity to address the ongoing healthcare needs of patients with PD, to reduce in-person clinic visits, and human exposures (among healthcare workers and patients) to a range of infectious diseases including COVID-19. However, there are still several challenges to widespread implementation of telemedicine including the limited performance of parts of the neurological exam, limited technological savvy, fear of loss of a personal connection, or uneasiness about communicating sensitive information. On the other hand, while we are facing the new wave of COVID-19 pandemic, patients and clinicians are gaining increasing experience with telemedicine, facilitating equity of access to specialized multidisciplinary care for PD. This article summarizes and reviews the current state and future directions of telemedicine from a global perspective.

Keywords: Parkinson’s disease; Telemedicine; movement disorders; telehealth.

Publication types

  • Review

MeSH terms

  • COVID-19 / complications
  • Health Services Accessibility
  • Humans
  • Pandemics
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / therapy*
  • Telemedicine*